Evolving evidence-based recommendations in T2D

This module summarises recent changes to global diabetes, cardiovascular disease, heart failure and kidney disease guidelines and updated label indications as a result of positive cardiovascular outcomes trial (CVOT) results.

Evolving evidence-based recommendations in T2D
Rate this content
  • Evolving evidence-based recommendations in T2D
  • Contents
  • CV disease occurs 10−15 years earlier in patients with diabetes compared with those without diabetes
  • Diabetes is a major CV risk factor
  • Evidence from CVOTs in patients with T2D has shown that SGLT2 inhibitors have beneficial effects on CV outcomes
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go